SCHEMBL6892544

SCHEMBL6892544

COC(=O)c1cccc2c1c1c(O)cc(C)cc1n2Cc1ccccc1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.44
KDM4E B2RXH2 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 3/20 0.44
NPSR1 Q6W5P4 3/20 0.44
GAA P10253 1/20 0.44
LMNA P02545 5/20 0.42
HTT P42858 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HIF1A Q16665 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TSHR P16473 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
PLA2G2A P14555 1/20 0.40
THRB P10828 1/20 0.40
RECQL P46063 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HSP90AA1 P07900 1/20 0.38
HSP90B1 P14625 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6689180 0.90 LMNA (0.47) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6888834 0.90 HSP90AA1 (0.41) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6897295 0.89 MAPT (0.48) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6894986 0.89 HSP90AA1 (0.38) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6898392 0.89 L3MBTL1 (0.44) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6894723 0.89 MAPT (0.45) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6891733 0.89 MAPT (0.43) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6896629 0.89 MAPK8 (0.47) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6773425 0.88 PLA2G2A (0.42) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6689196 0.88 GAA (0.47) MAPTKDM4EMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed